Moonlighting’s Founder, Dan Bensimhon, M.D., named Co-Recipient of LeBauer Visionary Award
Posted on 03.02.16

Over 300 community and business leaders attended the American Heart Association’s 2016 Guilford Heart Ball raising nearly $230,000 for heart disease and stroke research and prevention education.  Dr. Dan Bensimhon and Dr. Peter Van Trigt both received the LeBauer Visionary Award.  Cone Health and the AHA established the LeBauer Visionary Award last year, recognizing those individuals who have made a significant contribution to improving the cardiovascular health of our community and region, through exceptional patient care, innovative research and treatments, and active participation and contributions toward community health care causes.

“The VAD program has been successful because we started the program for the right reason–patient centered care for those heart failure patients without other options. We also used a team approach from the very beginning, which I firmly believe improves outcomes. Receiving an award like this from colleagues who are providing the highest quality cardiac care on a daily basis at Cone is a very humbling experience,” says Dr. Bensimhon. “But to be able to share the award with a surgeon of Dr. Van Trigt’s caliber and vision has made it one of the most special moments of my career and makes me want to work even harder to push the window of cardiac care for our community.”

Nominations were made by the Cone Health Heart and Vascular Center physicians and clinical leadership. A panel of heart and vascular experts, Cone Health leadership, and AHA leadership and volunteers reviewed the nominations and selected the finalists. Dr. Daniel R. Bensimhon is a cardiologist at Cone Health Medical Group HeartCare, and Dr. Peter Van Trigt is a Cardiothoracic Surgeon for Cone Health Medical Group – Triad Cardiac and Thoracic Surgeons. Together, Bensimhon and Van Trigt were recognized for revolutionizing care in Greensboro by developing an innovative, top performing and lifesaving left ventricular assist device (LVAD) program.

You can read the entire press release by clicking